Aurobindo Pharma Revenue History — Quarter by Quarter

Aurobindo Pharma's revenue moved from ₹6,850 Cr in Q1 FY24 to ₹8,646 Cr in Q3 FY26, a 26.2% change over 11 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

Quarter	Revenue (₹ Cr)	YoY Change
Q3 FY26	₹8,646 Cr	—
Q2 FY26	₹8,286 Cr	+6%
Q1 FY26	₹7,868 Cr	+4%
Q4 FY25	₹8,382 Cr	+11%
Q3 FY25	₹7,979 Cr	—
Q2 FY25	₹7,796 Cr	+8%
Q1 FY25	₹7,567 Cr	+10%
Q4 FY24	₹7,580 Cr	+17%
Q3 FY24	₹7,352 Cr	+14.7%
Q2 FY24	₹7,219 Cr	+25.8%
Q1 FY24	₹6,850 Cr	+9.9%

What management said about revenue

Q3 FY26 · EBITDA margin target of 20-21% for FY26

Management expects to achieve EBITDA margins on the higher side of 20-21% for FY2026, driven by Pen G ramp-up, injectable growth, and cost efficiencies.

Q3 FY26 · Pen G production to exceed 10,000 metric tons annualized in next 12 months

Based on current production levels, the company expects to produce more than 10,000 metric tons on an annualized basis over the next 12 months.

Q3 FY26 · Dayton facility to contribute significantly from FY27

The Dayton facility has transitioned to commercial phase and will begin contributing revenues significantly from FY2027 onwards.

Q2 FY26 · Europe to exceed EUR 1 billion annual revenue by FY26 end

European business on track to comfortably surpass EUR 1 billion annual revenue milestone by end of FY26, driven by consistent growth across major markets.

Q2 FY26 · Biosimilar denosumab EU submission in April 2026

Marketing authorization application for denosumab biosimilar to be submitted to EMA in April 2026; FDA submission expected in July quarter of 2026.

Q1 FY26 · China facility to break even at EBITDA by Q3 FY26

The China facility, with initial capacity of 2 billion+ units, is expected to break even at EBITDA level by Q3 FY26.

Q1 FY26 · PNG plant to generate healthy EBITDA from Q3 FY26

The PNG plant resumed operations and is expected to generate healthy EBITDA from Q3 onwards as yields improve.

Q1 FY26 · European business to cross €1B annual revenue by FY26 end

Management expects European formulations to exceed €1 billion in annual revenues by the end of FY26.

Q4 FY25 · High single-digit revenue growth in FY26 excluding transient products

Management expects revenue growth of 8-9% in FY26, excluding the contribution from transient products like Revlimid.

Q4 FY25 · China OSD plant to contribute revenues in FY26

The China plant, commercialized in FY25, is expected to contribute revenues in FY26 and turn breakeven or slightly positive.

Q3 FY25 · FY25 EBITDA margin guidance of 21%-22%

Management reaffirmed achieving 21%-22% EBITDA margin for FY25, despite Q3 margin of 20.4%, citing stronger Q4 with increased transient sales and operational efficiencies.

Q3 FY25 · China plant to contribute from FY26

The China OSD plant (2B units capacity) commercialized in November 2024, expected to ramp up and contribute to revenues in FY26, initially supplying Europe.